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Abstract
Genetic factors have been implicated in stroke risk but few replicated associations have been
reported. We conducted a genome-wide association study (GWAS) in ischemic stroke and its
subtypes in 3,548 cases and 5,972 controls, all of European ancestry. Replication of potential
signals was performed in 5,859 cases and 6,281 controls. We replicated reported associations
between variants close to PITX2 and ZFHX3 with cardioembolic stroke, and a 9p21 locus with
large vessel stroke. We identified a novel association for a SNP within the histone deacetylase 9
(HDAC9) gene on chromosome 7p21.1 which was associated with large vessel stroke including
additional replication in a further 735 cases and 28583 controls (rs11984041, combined P =
1.87×10−11, OR=1.42 (95% CI) 1.28-1.57). All four loci exhibit evidence for heterogeneity of
effect across the stroke subtypes, with some, and possibly all, affecting risk for only one subtype.
This suggests differing genetic architectures for different stroke subtypes.
Cerebrovascular disease (stroke) is one of the three most common causes of death and the
major cause of adult chronic disability (1). Stroke represents an increasing health problem
throughout the world as the proportion of elderly increases, and is an important cause of
dementia and age-related cognitive decline. While conventional risk factors such as
hypertension account for a significant proportion of stroke risk, much remains unexplained
(2). Twin and family history studies suggest genetic factors are responsible for some of this
unexplained risk (3). Stroke is a syndrome rather than a single disease, and subtypes of
stroke are caused by a number of different specific disease processes. About 80% of stroke
is ischemic; the three most common ischemic stroke subtypes are large vessel,
cardioembolic and small vessel (lacunar) stroke. Genetic epidemiological studies show
heterogeneity between stroke subtypes, the large vessel subtype being more strongly
associated with family history (4). SNPs associated with atrial fibrillation were found only
to be significantly associated with cardioembolic stroke (5,6), and a 9p21 variant initially
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associated with coronary artery disease and atherosclerosis only associated with large vessel
stroke (7). This suggests that different genetic variants can predispose to different subtypes
of ischemic stroke.
To date there have been few genome wide association studies (GWAS) in ischemic stroke
and few replicable associations have been identified (8). To further understand the genetic
basis of ischemic stroke, we undertook a GWAS as part of the Wellcome Trust Case Control
Consortium 2 (WTCCC2). We hypothesised that associations might be present only with
specific stroke subtypes. To investigate this, cases were classified into stroke subtypes
according to the pathophysiological TOAST classification (9), using clinical assessment as
well as brain and vascular imaging where available (see Online Methods). Association
analyses were performed on all ischemic stroke combined (including individuals not further
classified by stroke subtype), and also the three major stroke subtypes: large vessel, small
vessel and cardioembolic stroke. Discovery samples were of European ancestry and were
genotyped on Illumina arrays (see Online Methods). Following quality control, the
discovery set consisted of 3,548 cases (2,374 British, 1,174 German) and 5,972 controls
(5,175 British WTCCC2 common controls, and 797 German controls) genotyped on an
overlapping set of 495,851 autosomal SNPs (Table 1 and Online Methods). Within the
British and German data, cases and controls were well matched for ancestry (see Online
Methods and Supplementary Figure 1). We therefore performed association analysis
separately in the two groups and combined them using a fixed effect meta-analysis
approach. A two-stage replication study was performed in 5,859 cases (3,863 European,
1,996 American) and 6,281 controls (4,554 European, 1,727 American) all of self-reported
European ancestry. (Table 1 and Online Methods). Full details of the cohorts are available in
the Supplementary material. and Supplementary Table 1.
Table 2 shows results at previously reported loci and Figure 1 shows the association analysis
results across the autosomes. We replicated an association between cardioembolic stroke
and variants close to the PITX2 gene and also a SNP in the ZFHX3 gene, both of which
were initially associated with atrial fibrillation, a well recognised risk factor for stroke
(5,6,10). We also replicated a previously reported association between large vessel stroke
and the 9p21 region (7). As we, and others, already reported (11,12), we did not confirm the
previously published association between all stroke and variants in the 12p13 region (13,
14).
Thirty-eight previously unreported loci showed potential association for all stroke or one of
the stroke subtypes in the discovery samples, and we further investigated these loci in the
European replication samples by genotyping 43 SNPs covering these loci as well as 7 SNPs
to cover the previously reported loci (Supplementary Table 2). Thirteen of these previously
unreported loci and the previously reported loci were taken forward to replication in the
American samples with genotyping of 20 SNPs covering these regions (Supplementary
Table 3). Most replication samples were genotyped using Sequenom assays; for those
previously typed with GWAS chips we used genotype imputation where the SNP was not
directly typed (see Supplementary Tables 2 and 3 and Online Methods). A SNP at
chromosome 7p21.1 (rs11984041) showed evidence of association with large vessel stroke
in the discovery data (P=1.07×10−5) and in the joint European and US replication data in the
same direction (one-sided P=7.9×10−5). As a further check, we investigated this SNP in
three further collections of large vessel cases and matched controls (735 cases, 28583
controls in total), which we refer to as Stage 3 replication (see Online Methods for details).
The Stage 3 data also showed evidence in the same direction (one-sided P=2.25×10−4).
Together, the combined discovery and three-stage replication data provide strong evidence
for association (P=1.87×10−11) and suggest each copy of the A allele increases risk of large
vessel stroke by approximately 1.4 fold (Table 2 and Figure 2). This SNP is within the final
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intron of the gene HDAC9. The risk allele (A) frequency was 9.29% and 8.78% in the UK
and German discovery controls respectively.
Standard statistical tests of association between rs11984041 and each of cardioembolic and
small vessel stroke are not significant (discovery plus 2-stage replication p = 0.12, OR =
1.10, 95% CI = 0.98 – 1.23, and p = 0.06, OR = 1.13, 95% CI = 1.00 – 1.28 respectively). A
non-significant result could simply be due to a lack of power: lack of significance in itself
cannot rule out an effect in these subtypes. We investigated this potential genetic
heterogeneity further by formally comparing different statistical models for the effect of the
SNP on the different stroke subtypes. The models we compared were: (i) a model in which
the variant has no effect on risk for any of the subtypes (“null” model); (ii) a model in which
the SNP has the same effect on each subtype (“same effects” model); (iii) three models, in
each of which the SNP has an effect on one subtype, and no effect for the other two subtypes
(“LVD”, “SVD” and “CE” models respectively for the effect only in large vessel, small
vessel, and cardioembolic stroke); and (iv) a “correlated effects” model allowing different,
but correlated, effects for each subtype. We undertook the model comparison in a Bayesian
statistical framework (see Online Methods for details), for our new association around
HDAC9, as well as for the previously reported associations we confirmed as listed in Table
2. The results, based on the discovery and the first two stages of the replication, are shown
in Figure 3.
For rs11984041 at HDAC9 there is very strong evidence against the null model and both the
SVD and CE models (unsurprisingly given we ascertained this SNP on the basis of evidence
for an effect in LVD) and also strong evidence against the model in which the SNP has the
same effect in each subtype, thus demonstrating genetic heterogeneity across stroke
subtypes at this SNP. The greatest posterior weight rests on the model in which there is only
an effect for large vessel disease, with some weight on the correlated effects model, and in
this model the posterior distributions on effect size for SVD and CE stroke are concentrated
on much smaller effect sizes than for LVD.
In our data, heterogeneity is also seen at rs2383207 in the 9p21 region, a locus associated
with heart disease and related phenotypes, and previously associated with large vessel
stroke. Most support is for the model in which the effect sizes for the three stroke subtypes
are correlated but there is also substantial weight on the model in which there is only an
effect for large vessel stroke. The same analyses in our data for the top SNPs in the regions
previously associated with cardioembolic stroke (PITX2 region, rs1906599, and ZFHX3
regions, rs12932445) show strong support for the model in which these SNPs only affect
risk for cardioembolic stroke. Together these analyses provide compelling evidence for
heterogeneity of genetic effects between stroke subtypes.
The association with rs11984041, in the gene HDAC9, implicates a novel region of the
genome in an individual’s susceptibility to stroke. Any association with stroke could be
mediated via associations with intermediate cardiovascular risk factors that themselves
increase large vessel stroke risk. Our study design does not allow a direct assessment of this,
as such risk factors were not available for control individuals. However, to date no
associations have been reported between rs11984041 or correlated SNPs and hypertension
(15), hyperlipidaemia (16), or diabetes (17) from large-scale GWAS of these risk factors.
Association of genetic variants surrounding HDAC9 are represented in Figure 4. All variants
showing an association signal reside within a peak between two recombination hotspots and
encompass the tail end of HDAC9. The downstream genes TWIST1 and FERD3L are
physically relatively close to the identified peak and cannot be excluded as possible
mechanisms via which genetic variants may exert cis-effects on the large vessel stroke
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phenotype. HDAC9 is a member of a large family of genes that encode proteins responsible
for deacetylation of histones, and therefore regulation of chromatin structure and gene
transcription (18). HDAC9 is ubiquitously expressed, with high levels of expression in
cardiac tissue, muscle and brain (19). Although known as histone deacetylases, these
proteins also act on other substrates (20) and lead to both upregulation and downregulation
of genes (21).
The mechanism by which variants in the HDAC9 region increase large vessel stroke risk is
not immediately clear. The specific association with this stroke subtype would be consistent
with the association acting via accelerating atherosclerosis. The HDAC9 protein inhibits
myogenesis and is involved in heart development (19) although deleterious effects on
systemic arteries have not yet been reported. Alternatively it could increase risk by altering
brain ischaemic responses and therefore have effects on neuronal survival. The protein has
been shown to protect neurons from apoptosis, both by inhibiting JUN phosphorylation by
MAPK10 and by repressing JUN transcription. HDAC inhibitors have been postulated as a
treatment for stroke (22).
It is not uninformative that a large GWAS (~3,500 cases, ~6,000 controls) failed to find any
novel associations for the combined phenotype of ischemic stroke. It may be that the genetic
architecture of the disease involves fewer variants of more moderate effect than many other
diseases, and/or that these happen not to be well tagged by the Illumina 660-W chip used in
the study. On the other hand, as our data demonstrate, all the known loci exhibit genetic
heterogeneity across the stroke subtypes, with at least some, and possibly all, affecting only
a single subtype. This supports the possibility that distinct subtypes of the disease have
differing genetic architectures. However this is based on only four loci and does not exclude
the possibility that future loci associated with stroke may predispose to all ischaemic stroke.
Clinical classification of disease into subtypes is not perfect. Since errors in classification
would reduce power to detect heterogeneity, our findings of homogeneity within classes
indirectly reinforces the value of current classification methods. Because GWAS studies to
date, including the one reported here, have had relatively small sample sizes for each disease
subtype (and hence are underpowered for common variants of small effect), it remains
possible, and indeed a priori likely, that the range of effect sizes for each subtype will be
similar to those for other common diseases. This suggests that future genetic studies should
study adequate sample sizes for particular subtypes of ischaemic stroke, rather than for the
disease as a whole.
In summary, in this largest GWAS study of ischemic stroke conducted to date, we identified
a novel association with the HDAC9 gene region in large vessel stroke with an estimated
effect size which is at the larger end for GWAS loci (OR 1.38, 95% CI 1.22-1.57 from
replication data). We also replicated three other known loci, and showed genetic
heterogeneity across subtypes of the disease for all four stroke loci. This genetic
heterogeneity seems likely to reflect heterogeneity in the underlying pathogenic
mechanisms, and reinforces the need for separate consideration of stroke subtypes in the
research and clinical context.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX
Methods
Study subjects
All subjects were of self-reported European ancestry. Patients were classified into mutually
exclusive etiologic subtypes according to the Trial of Org 10172 in Acute Stroke Treatment
(TOAST) (9). TOAST classification was performed in all stroke cases. The TOAST system
has a category of “etiology unknown” which includes cases in which no cause has been
found due to insufficient investigation, as well as cases where no cause is found despite full
investigation. This “unknown” group was not analysed in subtype analyses described in this
paper which focussed only in those patients where there were appropriate investigations to
assign one of three subtypes; large vessel disease, cardioembolic and small vessel disease.
The unknown cases were only included in the analyses of all ischaemic stroke which did not
take into account subtype.
Our main analyses were of associations with all ischemic stroke and with the three main
subtypes: large vessel, cardioembolic and small vessel stroke. We performed additional
analyses in the discovery populations with young stroke (age <70 years at first stroke), and
with the presence of large vessel stenosis and, separately, the presence of cardioembolic
source, irrespective of assigned subtype. These last two analyses allowed inclusion of
patients whose data was excluded from individual subtype analysis because they had more
than one potential stroke subtype. Details of individual populations are given in Table 1 and
in supplementary material.
DNA sample preparation
This was performed as described in the Supplementary Material.
GWA genotyping
Samples from the cases were genotyped at the WTSI on the Human660W-Quad (a custom
chip designed by WTCCC2 comprising Human550 and circa 6000 common CNVs from the
Structural Variation Consortium (24)). Samples from British control collections were
genotyped on the Human1.2M-Duo (a WTCCC2 custom array comprising Human1M-Duo
and the CNV content described above). Bead intensity data was processed and normalized in
BeadStudio; data for successfully genotyped samples was extracted and genotypes called
within collections using Illuminus(25). German controls were typed on Illumina Human
550k platform, and intensity data was processed and normalized for each sample in
GenomeStudio using the Illumina cluster file HumanHap550v3.
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GWA quality control
Samples—As previously described (26,27), we removed samples whose genome-wide
patterns of diversity differed from those of the collection at large, interpreting them likely to
be due to biases or artefacts. To do so we used a Bayesian clustering approach (28) to infer
outlying individuals on the basis of call rate, heterozygosity, ancestry, and average probe
intensity. To obtain a set of putatively unrelated individuals we used a hidden Markov model
(HMM) to infer identity by descent and then iteratively removed individuals to obtain a set
with pair-wise identity by descent <5%. To guard against sample mishandling we removed
samples if their inferred gender was discordant with recorded gender, or if <90% of the
SNPs typed by Sequenom on entry to sample handling (see above) agreed with the genome-
wide data. Our final discovery dataset consisted of 3548 cases (2374 British, 1174 German)
and 5972 controls (5175 British, 797 German) following sample quality control
(Supplementary Table 4). A full breakdown of samples by cohort and subtype is in Table 1.
SNPs—A measure of (Fisher) information for allele frequency at each SNP was calculated
using SNPTEST (see URLs). Autosomal SNPs were excluded if this information measure
was below 0.98, if minor allele frequency was <0.01%, if the SNP had >5% missing data, or
if Hardy Weinberg p-value was <1×10−20 in the case or control collections. In the 58C,
UKBS and case data set, association between SNP and the plate on which samples were
genotyped was calculated and SNPs with a plate effect p-value <1×10−6 were also excluded.
An additional 45 SNPs were removed following visual inspection of cluster plots. A
breakdown of the number of SNPs excluded is provided in Supplementary Table 5. Only
SNPs genotyped on all the case and control collections were considered, leaving 495,851
autosomal SNPs after quality control. Hardy Weinberg p-values for the SNPs taken to
replication are given in Supplementary Table 6.
Initial replication genotyping and quality control
Genotyping of European replication samples was carried out at the WTSI using Sequenom
iPLEX Gold assay and genotyping of the US samples at the Broad Institute, Boston, USA
using the Sequenom platform, with the exception of the GEOS Study, in which genotyping
was carried out using Illumina Human Omni1-Quad. Imputation to HapMap3 using
BEAGLE software program (29) was performed. Individual samples were excluded from
analysis if they had call rates <80% or if reported gender was discordant with gender
specific markers. We removed pairs of samples showing concordance indicative of being
duplicates.
The PoBI samples were genotyped on the custom Human1.2M-Duo array using Illumina’s
Infinium platform and subjected to similar quality control as described above; for each SNP
used in replication the cluster plot was visually inspected.
The PROCARDIS controls were genotyped with the Illumina HumanHap 610 Quad
beadchip. PCA with HapMap2 reference population data allowed exclusion of individuals
with non-European ancestry. Subsequent PCA with HapMap3 on German stroke samples
with GWAS data and additional European reference population data, showed German
PROCARDIS controls had similar ancestry to German stroke cases (data not shown).
Third stage replication of rs11984041 SNP
For the deCODE cases and controls genotyping was performed on 317K or 370K Illumina
chips. The SNP rs11984041 was imputed using HapMap. ASGC cases and control samples
were genotyped on the Illumina HumanHap610-Quad array, SNP rs11984041 was directly
genotyped. Milan cases samples were genotyped using Illumina Human610-Quadv1_B or
Human660W-Quad_v1_A beadchip; both include the rs11984041 SNP. Milan controls were
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genotyped with the Illumina HumanHap 610 Quad beadchip. PCA with HapMap3 on the
Italian stroke samples showed that Italian PROCARDIS controls had similar ancestry to
Italian stroke cases.
Genotype imputation
This was performed as described in the Supplementary Material.
Association analysis
We performed single SNP analysis separately in the British and German discovery data sets
under an additive model (on the log-odds scale) using missing data likelihood score tests as
implemented in SNPTEST. We conducted a fixed effect meta-analysis in R to combine the
evidence of association, averaging the estimated effect size parameters associated with
genotype risk across the two data sets, weighting the effect size estimates by the inverse of
the square of corresponding standard errors. P-values were calculated assuming the
combined data z-score to be normally distributed. The British and German cohorts had an
inflation factor ranging from 1.014 to 1.058 and from 1.011 to 1.044 respectively, depending
on the stroke subtype considered (Supplementary Figure 1). This analysis was also
performed separately in males and females.
We also conducted a genome-wide scan analysis based on a Bayesian model which allows
each stroke subtype to have its own effect and models relationships between these effects
using a hierarchical prior specification. The same effects were assumed for the
corresponding stroke subtype in both British and German populations (Supplementary Table
2).
Finally we performed a genome-wide scan using GENECLUSTER (31). This estimates
genealogical tree of the case-control sample at a position of interest based on the genealogy
of a reference panel (HapMap2 CEU in our case), by simultaneously phasing and clustering
the case and control haplotypes to the tips of the reference genealogy. The method detects
signals of association in the form of differential clustering of cases and controls underneath
a branch, or a number of branches, in the estimated genealogy, which is equivalent to
associations due to haplotypic effects or allelic heterogeneity (Supplementary Table 2).
Replication
Replication of potential associations found in the GWAS of the discovery cohorts was
conducted in two stages in independent European and American samples. We investigated in
the European replication cohorts 50 SNPs, that either were in loci reported in the literature
from previous GWAS, or showed potential associations (P<1×10−5) with all stroke or one of
the stroke subtypes in analysis of the discovery data set, and showed consistent direction of
effect in both British and German cohorts (Supplementary Table 2). This threshold was
chosen based on resources available for replication. After analysis of the combined results of
the discovery and European replication populations 20 of these SNPs were taken forward to
second stage replication in the American samples (Supplementary Table 3).
Association analysis was performed in each replication cohort separately via a logistic
regression assuming an additive genetic model. Evidence of association across the
replication data was combined using a fixed effect meta-analysis as previously described.
Data on the presence or absence of a cardioembolic source or large vessel stenosis
(irrespective of assigned TOAST subtype) were not available in all of replication cohorts.
For replication of SNPs identified due to association with these phenotypes in the discovery
cohorts, we assessed association in the replication cohorts with the cardioembolic or large
vessel stroke subtypes respectively.
and Page 7
Nat Genet. Author manuscript; available in PMC 2012 September 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Bayesian model comparison
Details of this analysis are given in the Supplemental Material.
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Figure 1. Genome-wide association results at autosomal SNPs in combined British and Germany
discovery samples
All ischemic stroke (top panel), large vessel stroke (second panel), small vessel stroke (third
panel) and cardioembolic stroke (final panel). Loci previously reported in the literature for
particular stoke subtypes (Table 2) are shown in black, with the new HDAC9 locus shown in
red. In addition the combined p-values for discovery study and stages one and two of the
replication study, at the top SNPs for these loci, are marked with diamonds.
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Figure 2. Forest plot for the associations between rs11984041 and large vessel stroke in discovery
and replication collections
The blue lines show the 95% confidence intervals of the log odds-ratio (OR) for each cohort,
with the area of each square proportional to the inverse of the standard error. The diamonds
indicate the 95% confidence interval for, from top to bottom, the discovery summary
(combined British and German discovery collections), combined across collections within
each of the three replication stages, the replication summary (combined across all three
replication stages) and the overall summary (all discovery and replication collections
combined). Evidence was combined across collections via an inverse-variance weighted
fixed-effect meta-analysis. There was no evidence of heterogeneity of effect across
collections (P = 0.92).
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Figure 3. Genetic heterogeneity of different stroke sub-types for the 4 loci with significant
associations: HDAC9, PITX2, 9p21(CDKN2A/CDKN2B) and ZFHX3
Bar plots show the posterior probabilities on the models of association: no effect in any
subtype (Null), same effect in all subtypes, correlated effects across subtypes or subtype
specific effects (see main text). Models are a priori assumed to be equally likely. Bayes
factors, which compare the evidence (marginal likelihood) between any pair of models, can
be calculated as the ratio of the posterior probability assigned to each model as reported
under each bar of the plot. Accompanying density plots show the marginal posterior
distribution on the odds ratio of the risk allele for each stroke subtype assuming a model of
correlated effects (see methods for specification of priors). These analyses were performed
using both discovery and replication samples (stage 1 & 2).
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Figure 4.
Plot of association signals around rs11984041 for large vessel stroke in the combined British
and German discovery samples. SNPs are coloured based on their correlation (r2) with the
labelled hit SNP which has the smallest P-value in the region. r2 is calculated from the
WTCCC2 control data. The bottom section of each plot shows the fine scale recombination
rates estimated from HapMap data, and genes are marked by horizontal red lines. Arrows on
the horizontal red lines denote direction of transcription, and black rectangles are exons.
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